Trial Profile

Histocompatibility Leukocyte Antigen (HLA)-A 2402 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Montanide ISA-51; VEGFR-1 peptide vaccine; VEGFR-2 peptide vaccine
Indications Retinal disorders; Wet age-related macular degeneration
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

16 Oct 2012 Biomarkers information updated
01 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
02 Dec 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com